Promising Data on First Inhibitor of HIF-2a for Renal Cell Carcinoma
Preclinical data indicates that lead investigational compound PT2385 suppresses gene expression essential for tumor growth, proliferation, and angiogenesisPhase 1 study of PT2385 ongoing; first clinical stage HIF-2a program.04/20/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology